Lexicon Pharmaceuticals

Lexicon Pharmaceuticals

Biotechnology
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

$798.7M

Market Cap • 9/25/2026

1995

(31 years)

Founded

2000

(26 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

4,6

P/S

19,3

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

0,4

EPS

—

Market Cap

Market Cap

798,7M

EV

659,5M

EV/Revenue

15,9

EV/EBITDA

-12,2

EV/EBIT

-12,1

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

0,3%

Total Yield

0,3%

Payout

0%

Retained Earnings

-2,1B

Profitability

Gross Margin

99,1%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

145,3%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

—

% PPE

3,4%

% Goodwill

17,8%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

42,4%

CAGR OCF 5Y

-11,8%

Leverage

N.D./EBITDA

2,6

Debt/Equity

0%

Current Ratio

13,4

Quick Ratio

13,1

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium